Vimal Mehta - Jun 25, 2021 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role: CEO, President and Secretary, Director
Signature: /s/ Vimal Mehta
Stock symbol: BTAI
Transactions as of: Jun 25, 2021
Transactions value $: -$14,589,493
Form type: 4
Date filed: 6/29/2021, 05:23 PM
Next filing: Feb 14, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BTAI	Common Stock	Sale	-$14.6M	-473K	-5.25%	$30.83	8.55M	Jun 25, 2021	See footnotes	F1, F2
holding	BTAI	Common Stock						2K	Jun 25, 2021	By Spouse
holding	BTAI	Common Stock						9.96K	Jun 25, 2021	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions.
F2	These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Content

On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions.

These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.